UK scientist taps investors to fund Alzheimer’s drug trial
British baroness Susan Greenfield, the founder of Neuro-Bio, is raising funds in Australia to begin human trials of a new drug to fight the elusive disease.
British baroness Susan Greenfield, the founder of Neuro-Bio, is raising funds in Australia to begin human trials of a new drug to fight the elusive disease.
Allan Gray’s Simon Mawhinney says there is no value in the buy now pay later sector, as Humm shareholder Andrew Abercrombie fights to stop the group’s sale.
Investors should seek out private equity funds, rather than floats like Rivian, according to the co-founder of one of Europe’s largest PE fund managers.
The outspoken former chairman of Humm has started a shareholder campaign to trigger a ‘no’ vote against the $320m sale of its BNPL unit to Latitude, labelling offer the ‘too low’.
Telstra and TPG say their proposed regional network sharing partnership will increase choice for customers in the regions and in capital cities but Optus strongly disagrees.
A new Agribusiness Index on the ASX should drive an increase in capital for primary producers as they look to expand.
The non-bank lender reveals its buy now, pay later business is unprofitable and urged investors to back its $320m sale to Latitude Financial.
The bank will sell its Advance business and transfer billions in funds under administration to Mercer as the global asset manager looks to expand further.
The former NSW premier has returned to the markets and is taking the chair of Geoff Wilson’s Future Generation Australia – but won’t rule out a return to politics.
M&A activity involving unlisted targets this year will likely centre around technology and health sectors, according to Jeremy Wickens.
Original URL: https://www.theaustralian.com.au/author/tansy-harcourt/page/40